Mycotoxin-deactivating aptamers, especially DNA aptamers, bind to mycotoxins in feed and feed ingredients resulting in the reduction or elimination of toxic and carcinogenic effects of mycotoxins. The invention also discloses a composition comprising a mycotoxin-deactivating aptamer, a binding agent, a biotransforming agent and an antioxidant for detoxifying mycotoxins in feeds. In addition, the invention teaches the methods of preparing the mycotoxin-deactivating aptamer-based composition and also the methods of using it as a feed additive. Furthermore, the invention relates to the use of the mycotoxin-deactivator/s alone, or in a composition comprising the aptamers and other mycotoxin-detoxifying agents, in feeds and feed ingredients for detoxifying the major mycotoxins such as aflatoxins, deoxynivalenol, zearalenone, fumonisins and ochratoxin A.

Mycotoxin-deactivating aptamers, especially DNA aptamers, bind to mycotoxins in feed and feed ingredients resulting in the reduction or elimination of toxic and carcinogenic effects of mycotoxins. The invention also discloses a composition comprising a mycotoxin-deactivating aptamer, a binding agent, a biotransforming agent and an antioxidant for detoxifying mycotoxins in feeds. In addition, the invention teaches the methods of preparing the mycotoxin-deactivating aptamer-based composition and also the methods of using it as a feed additive. Furthermore, the invention relates to the use of the mycotoxin-deactivator/s alone, or in a composition comprising the aptamers and other mycotoxin-detoxifying agents, in feeds and feed ingredients for detoxifying the major mycotoxins such as aflatoxins, deoxynivalenol, zearalenone, fumonisins and ochratoxin A.

Provided herein, inter alia, are compositions comprising oxygen tolerant strains of Megasphaera elsdenii and methods of making and using the same to promote improvement of one or more metrics in an animal, such as increased bodyweight/carcass gain, increased feed intake, decreased feed conversion ratio (FCR), decreased medical costs, decreased transition period, decrease use of antibiotics, and reduced mortality.

The present disclosure provides feed composition comprising at least one cyclopropenoid fatty acids or at least one conjugated linoleic acid and at least one cyclopropenoid fatty acids with normal or basal feed. After administration of one of the feed compositions, improved health aspects, reduced health issues, reduced mortality, increased carcass gain and repartitioning nutrients to muscles, and controlled carcass iodine value in non-human animals as compared to a control group not fed with the feed composition.

The present disclosure provides feed composition comprising at least one cyclopropenoid fatty acids or at least one conjugated linoleic acid and at least one cyclopropenoid fatty acids with normal or basal feed. After administration of one of the feed compositions, improved health aspects, reduced health issues, reduced mortality, increased carcass gain and repartitioning nutrients to muscles, and controlled carcass iodine value in non-human animals as compared to a control group not fed with the feed composition.

The present disclosure is directed to genetically modified bacteria that produce a diffusible signal factor (DSF). The disclosure also provides methods for treating or preventing Salmonella infection/invasion in a subject. The disclosure further provides vectors and compositions for carrying out the methods disclosed herein.

Provided is a method of treating a disease caused by a nidovirus that encodes Nsp15, such as a coronavirus, an arterivirus, or a torovirus, in a subject in need thereof comprising administering a therapeutically effective amount of an active agent selected from 3′-uridylic acid, 5′-uridylic acid, citrate, methacycline, meclocycline sulfosalicylate, mitoxantrone, epirubicin hydrochloride, daunorubicin hydrochloride, sorafenib, sunitinib malate, primaquine diphosphate, closantel, isopropyl ester of N4-hydroxycytidine, GpU dinucleotide or derivatives thereof, and tipiracil or N-substituted derivatives thereof. Further provided are a method of inhibiting an Nsp15 endoribonuclease of a nidovirus that encodes Nsp15 and compounds of formulas (I′) and (II′).

Compositions including odd chain saturated fatty acids, and salts and derivatives thereof, and methods for treatment or prophylaxis of conditions related to healthy body weight maintenance are provided, including compositions and methods for supporting a healthy body weight, for satiety/reduced calorie consumption, and/or for efficient fat metabolism.

A product includes dehydrated flesh of green bananas and/or plantains and/or dehydrated non-flesh banana plant material. The product may be used as an animal or human feed product, a nutraceutical product or a component of a nutraceutical product. The processes for producing the product are also disclosed.

Some embodiments of the present disclosure include a dried product for providing a supplement to a horse. The dried product may include a mixture of a horse supplement, beet pulp, water, horse feed, a safflower oil/vitamin E oil mixture, ground alfalfa, white flour, sea salt, fenugreek, ascorbic acid, and fruit pectin or apple pectin, wherein the product is in the form of a compressed product, such as a compressed round disk. For example, in an embodiment, the compressed round disk may have a diameter of about 2.5 inches and a thickness of about 1 inch.